U.S. Markets closed

Oxford BioMedica PLC (OXB.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
8.73-0.09 (-1.02%)
At close: 4:35PM BST

Oxford BioMedica PLC

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783000
http://www.oxfordbiomedica.co.uk

SectorHealthcare
IndustryBiotechnology
Full Time Employees288

Key Executives

NameTitlePayExercisedAge
Mr. John DawsonCEO & Exec. DirectorN/AN/A57
Mr. Timothy William WattsCFO, Company Sec. & Exec. Director399kN/A59
Mr. Peter NolanChief Bus. Officer & Exec. DirectorN/AN/A64
Dr. James Miskin Ph.D.Chief Technology OfficerN/AN/AN/A
Dr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company’s products under development include OXB-102 that has completed Phase I/II trial for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; OXB-301, a cancer vaccine which is in a Phase I/II trial; and OXB-302, which is based on an autologous T-cell that is engineered using a lentiviral vector to express a chimeric antigen receptor targeting multiple cancers, as well as OXB-201 that is in Phase I/II trial for the treatment of ‘wet’ age-related macular degeneration and diabetic retinopathy. It is also developing SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, a gene-based therapy that is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Sanofi, GlaxoSmithKline, Novartis, Green Cross LabCell, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Corporate Governance

Oxford BioMedica PLC’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.